March 21, 2023Open Access

Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Our findings regarding the heterogeneity in outcomes for patients with dnMBC could guide future revisions of the current American Joint Committee on Cancer staging guidelines for patients with newly diagnosed stage IV disease. Our findings should be independently confirmed.

KI fragen

Bookmark

View Full Paper

Cite This Study

Plichta et al. (Tue,) studied this question.

synapsesocial.com/papers/69d8153f7392c8ce61bee7df https://doi.org/https://doi.org/10.1200/jco.22.02222

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1An introduction to recursive partitioning: Rationale, application, and characteristics of classification and regression trees, bagging, and random forests.2009 · 2,611 citations
2Construction and validation of a practical prognostic index for patients with metastatic breast cancer.1998 · 143 citations
3Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update2018 · 1,478 citations
4De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype2017 · 76 citations
5Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population2016 · 60 citations

KI fragen

Bookmark

View Full Paper